Evidence map›Paper›PMID 41881528›Full record

ArticleBMJ open2026

Study protocol for testing a mobile app designed to improve health literacy and self-management in people with bronchiectasis: the ANIMA app.

Jessica de Campos Medeiros, Adria Cristina da Silva, Antonio Casanova Junior da Silva Lima, Cristiano Torezzan, Ricardo Afonso Alves Dos Santos, Monica Corso Pereira

Abstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jessica de Campos MedeirosUniversidade Estadual de Campinas - UNICAMP, Campinas, Brazil j154400@dac.unicamp.br.ORCID http://orcid.org/0000-0002-6627-3525
Adria Cristina da SilvaUniversidade Estadual de Campinas - UNICAMP, Campinas, Brazil.
Antonio Casanova Junior da Silva LimaUniversidade Estadual de Campinas - UNICAMP, Campinas, Brazil.ORCID http://orcid.org/0000-0002-2982-9184
Cristiano TorezzanUniversidade Estadual de Campinas - UNICAMP, Campinas, Brazil.
Ricardo Afonso Alves Dos SantosUniversidade Estadual de Campinas - UNICAMP, Campinas, Brazil.
Monica Corso PereiraUniversidade Estadual de Campinas - UNICAMP, Campinas, Brazil.ORCID http://orcid.org/0000-0002-7669-4841

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with bronchiectasis unrelated to cystic fibrosis (CF) present variability in daily symptoms. Recurrent episodes of worsening symptoms can have a negative impact on lung function and quality of life, as well as increasing costs and mortality. Daily symptom monitoring can improve patients' awareness of variations and support self-management. Mobile applications for tracking symptoms may encourage engagement, enabling problems to be identified early and potentially reducing exacerbations. METHODS AND ANALYSIS: This manuscript describes the protocol for a randomised controlled trial designed to evaluate a digital symptom-monitoring tool (ANIMA) for patients with bronchiectasis unrelated to CF patients. Eligible participants will be randomised by sealed, opaque envelopes to intervention (GR-A) or control (GR-C). Both groups will complete the Bronchiectasis Health Questionnaire (BHQ), Health Literacy Questionnaire (HLQ-BR); socioeconomic status will be assessed using a validated instrument. All will receive an educational leaflet. GR-A will use the ANIMA application for daily symptom monitoring, and a GR-C, which will continue with their usual healthcare follow-up without using the application. All participants will be followed for a period of 6 months. At the end of the 6 month follow-up, the baseline questionnaires (BHQ and HLQ-BR) will be reapplied in both groups, and the Telehealth Usability Questionnaire - Brazilian version will be administered exclusively to participants in the GR-A. The planned sample size is 86 participants (43 per group), with a minimum feasible recruitment target of 60 participants due to the limited eligible population and the fixed recruitment window. Data will be analysed using SPSS Statistics version 25 (IBM Corp., Armonk, NY, USA). Descriptive statistics will summarise baseline characteristics. Between-group comparisons will be performed with appropriate parametric or non-parametric tests according to data distribution. Primary analysis will follow the intention-to-treat principle, with a complementary per-protocol analysis considering participants completing at least 50% of planned assessments. Statistical significance will be set at p<0.05. Recruitment began in April 2025 and will continue until October 2025, with follow-up completion in April 2026. ETHICS AND DISSEMINATION: Approved by the Research Ethics Committee of the State University of Campinas (CAAE: 48830621.2.0000.5404). Results will be disseminated via peer-reviewed publications and conference presentations. TRIAL REGISTRATION NUMBER: Brazilian Clinical Trials Registry (ReBEC) - U1111-1313-6511. Registered prior to recruitment start. PROTOCOL VERSION: V.1.0 - August 2025.

Indexed as

BronchiectasisHealth LiteracyMobile ApplicationsSelf-ManagementHumansQuality of LifeRandomized Controlled Trials as TopicSurveys and QuestionnairesClinical TrialDigital TechnologyHealth LiteracyMobile ApplicationsPulmonary Disease

Identifiers

PMID41881528
PMCPMC13034362

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.